- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- E7 TCR
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 3,575
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Interventions
- Doxycycline monohydrate
- Drug
- Lead sponsor
- Rochester General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Critical Limb Ischemia
- Interventions
- Ixmyelocel-T, Placebo
- Biological · Other
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
- Conditions
- Asthma, Allergies
- Interventions
- Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage, Phlebotomy
- Biological · Procedure
- Lead sponsor
- Andrew D. Luster, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Secondary Myelofibrosis
- Interventions
- filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- The Canadian Blood and Marrow Transplant Group
- Network
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alopecia Areata
- Interventions
- Etrasimod, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Encinitas, California + 24 more
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
- Procedure · Drug · Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Cutaneous T-cell Lymphoma (CTCL),
- Interventions
- Forodesine 200 mg
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 16 more
- Conditions
- HIV Infections
- Interventions
- EP HIV-1090
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2005
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- aldesleukin, recombinant interferon alfa, sargramostim
- Biological
- Lead sponsor
- Cancer Treatment Centers of America
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Zion, Illinois
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 3 more
- Conditions
- Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
- Interventions
- AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab
- Procedure · Drug
- Lead sponsor
- Vijendra Singh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Biopsy, Ipilimumab, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, Therapeutic Conventional Surgery
- Biological · Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- Verapamil HCl, Placebo
- Drug · Other
- Lead sponsor
- Benjamin Bleier
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype, Adult T-Cell Leukemia/Lymphoma (ATLL)
- Interventions
- Cobomarsen
- Drug
- Lead sponsor
- miRagen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Interventions
- atorvastatin, Tacrolimus, methotrexate
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neuroblastoma, Osteosarcoma
- Interventions
- iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2044
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Chapel Hill, North Carolina
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
- Drug · Biological
- Lead sponsor
- Calimmune, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Advanced and/or Metastatic Solid Tumours
- Interventions
- CB307
- Drug
- Lead sponsor
- Crescendo Biologics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- cyclosporine
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 23
- States / cities
- Stanford, California • Aurora, Illinois • Berwyn, Illinois + 12 more
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Interventions
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing
- Biological · Drug · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Cancer
- Interventions
- ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
- Biological · Drug · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California